SMND-309_product_DataBase

Bioactivity

SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats[1][2].

In Vivo

SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue. SMND-309 also decreases the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment reduces the liver damage and the liver fibrosis grade. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver[1]. Animal Model:

Name

SMND-309

CAS

1065559-56-9

Formula

C18H14O8

Molar Mass

358.30

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Hou J, Tian J, Jiang W, Gao Y, Fu F.Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis.Eur J Pharmacol. 2011 Jan 10;650(1):390-5. [2]. Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J.Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats.Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23. [3]. Wang Y, Zhang J, Han M, et al. SMND-309 promotes neuron survival through the activation of the PI3K/Akt/CREB-signalling pathway. Pharm Biol. 2016;54(10):1982-1990.

PeptideDB

SMND-309

CAS: 1065559-56-9 F: C18H14O8 W: 358.30